BR112023011777A2 - Anticorpos contra integrina alfa 11 beta 1 - Google Patents

Anticorpos contra integrina alfa 11 beta 1

Info

Publication number
BR112023011777A2
BR112023011777A2 BR112023011777A BR112023011777A BR112023011777A2 BR 112023011777 A2 BR112023011777 A2 BR 112023011777A2 BR 112023011777 A BR112023011777 A BR 112023011777A BR 112023011777 A BR112023011777 A BR 112023011777A BR 112023011777 A2 BR112023011777 A2 BR 112023011777A2
Authority
BR
Brazil
Prior art keywords
beta
antibodies against
integrin alpha
against integrin
antibodies
Prior art date
Application number
BR112023011777A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Beneduce
Elma Kurtagic
W Meador James Iii
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of BR112023011777A2 publication Critical patent/BR112023011777A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112023011777A 2020-12-18 2021-12-17 Anticorpos contra integrina alfa 11 beta 1 BR112023011777A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127849P 2020-12-18 2020-12-18
US202163213973P 2021-06-23 2021-06-23
PCT/IB2021/061926 WO2022130318A2 (en) 2020-12-18 2021-12-17 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
BR112023011777A2 true BR112023011777A2 (pt) 2023-10-03

Family

ID=79021748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023011777A BR112023011777A2 (pt) 2020-12-18 2021-12-17 Anticorpos contra integrina alfa 11 beta 1

Country Status (13)

Country Link
US (1) US20240317865A1 (https=)
EP (1) EP4263605A2 (https=)
JP (1) JP2024505790A (https=)
KR (1) KR20230121831A (https=)
AU (1) AU2021400221A1 (https=)
BR (1) BR112023011777A2 (https=)
CA (1) CA3205574A1 (https=)
CL (1) CL2023001757A1 (https=)
CO (1) CO2023008544A2 (https=)
IL (1) IL303741A (https=)
MX (1) MX2023007302A (https=)
TW (1) TW202241946A (https=)
WO (1) WO2022130318A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127500A1 (en) 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3760722A4 (en) * 2018-03-01 2021-11-24 Hiroshima University MONOCLONAL ANTI-INTEGRIN ALPHA11 ANTIBODY AND USES THEREOF
WO2021127500A1 (en) * 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Also Published As

Publication number Publication date
AU2021400221A1 (en) 2023-07-13
MX2023007302A (es) 2023-09-04
US20240317865A1 (en) 2024-09-26
KR20230121831A (ko) 2023-08-21
AU2021400221A9 (en) 2025-03-13
WO2022130318A3 (en) 2022-08-04
EP4263605A2 (en) 2023-10-25
CL2023001757A1 (es) 2024-01-05
CA3205574A1 (en) 2022-06-23
WO2022130318A2 (en) 2022-06-23
IL303741A (en) 2023-08-01
CO2023008544A2 (es) 2023-07-10
TW202241946A (zh) 2022-11-01
JP2024505790A (ja) 2024-02-08

Similar Documents

Publication Publication Date Title
CL2021000291A1 (es) Constructos de anticuerpos para cldn18.2 y cd3
ECSP22083269A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
MA45747A (fr) Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
MX2023004054A (es) Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
BR112023024837A2 (pt) Anticorpos anti-ccr8
JOP20230239A1 (ar) أجسام مضادة للنكتين-4 واستخدامتها
MX2019006804A (es) Novedoso polipeptido y procedimiento de produccion de imp mediante el uso del mismo.
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
AR114112A1 (es) Anticuerpos de glipicano 3 y conjugados de los mismos
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112022011824A2 (pt) Anticorpos de cadeia pesada que se ligam a cd38
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo
AR121370A1 (es) Anticuerpos anti-cd19 humano
MX2020002243A (es) Anticuerpos utiles en diagnosis de cancer.
CL2022001673A1 (es) Anticuerpos contra la integrina alfa 11 beta 1.
SA523450167B1 (ar) أجسام مضادة لعامل التحول الوسيطي الظهاري واستخداماتها
CL2022001130A1 (es) Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas
MX2021015842A (es) Polipeptido variante de dihidrodipicolinato reductasa y procedimiento de produccion de l-treonina mediante el uso del mismo.
MX2022012740A (es) Composicion de fragancia.
BR112023011777A2 (pt) Anticorpos contra integrina alfa 11 beta 1
CL2021003556A1 (es) Cuerpo de carburo cementado en gradiente y método de fabricación del mismo.
CO2024000763A2 (es) Composiciones y métodos de los anticuerpos anti-pacap
BR112022024992A2 (pt) Formulações prontas para o consumo